DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® ...
Want to participate in a short research study? Help shape the future of investing tools and earn a $40 gift card! Fred Ors has been the CEO of IMV Inc. (TSE:IMV) since 2016, and this article will ...
If you own shares in IMV Inc. (TSE:IMV) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance ...
The ticking cash clock has forced IMV to act. Down to its last $21 million, the clinical-phase biotech has brought Stonegate Healthcare Partners onboard to explore strategic alternatives amid concerns ...
The newfound potential to clinically reengineer the human immune system has launched some of the most exciting research in the world of medical science. Immuno-oncology has created a beacon of hope ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today ...
(RTTNews) - Today's Daily Dose brings you news about Aldeyra's stock sales to two healthcare-focused investment funds, AstraZeneca teaming up with a contract research organization to accelerate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback